Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
December 22, 2023 16:30 ET
|
Cellectis Inc.
NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving...
Autolus Therapeutics Announces Changes to its Board of Directors
December 22, 2023 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Announces Changes to its Board of Directors
CARGO Therapeutics Reports Business Updates and Third Quarter 2023 Results
December 13, 2023 16:05 ET
|
Cargo Therapeutics, Inc.
SAN MATEO, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell...
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
December 09, 2023 20:30 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
Global CAR T-Cell Therapy Market to Surpass $15 Billion by 2030, Driven by Growing Prevalence of Multiple Myeloma and Lymphoma
December 08, 2023 08:18 ET
|
Research and Markets
Dublin, Dec. 08, 2023 (GLOBE NEWSWIRE) -- The "CAR T-cell Therapy Market Size, Share & Trends Analysis Report by Product (Abecma, Breyanzi), By Disease Indication (Lymphoma, Leukemia, Multiple...
CARGO Therapeutics Announces Scientific Advisory Board
December 06, 2023 08:05 ET
|
Cargo Therapeutics, Inc.
SAN MATEO, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CRGX), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell...
Monthly information on share capital and company voting rights
December 01, 2023 16:30 ET
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 ...
Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023
November 15, 2023 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023
Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
November 15, 2023 02:30 ET
|
Cellectis Inc.
Execution of binding subsequent investment agreement regarding contemplated additional equity investment of $140M by AstraZeneca, previously announced on November 1, 2023.Extraordinary shareholders’...
Exploring CAR-T Therapy: A New Era in Cancer Treatment
November 14, 2023 04:48 ET
|
Research and Markets
Dublin, Nov. 14, 2023 (GLOBE NEWSWIRE) -- The "CAR-T Therapy- Pipeline Insight, 2023" drug pipelines has been added to ResearchAndMarkets.com's offering. The research report delves into several...